Does the media favor ALGS or TNYA?

In the previous week, Tenaya Therapeutics had 4 more articles in the media than Aligos Therapeutics. MarketBeat recorded 6 mentions for Tenaya Therapeutics and 2 mentions for Aligos Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.76 beat Aligos Therapeutics' score of 0.46 indicating that Tenaya Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aligos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tenaya Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALGS or CRBU?

In the previous week, Caribou Biosciences had 8 more articles in the media than Aligos Therapeutics. MarketBeat recorded 10 mentions for Caribou Biosciences and 2 mentions for Aligos Therapeutics. Caribou Biosciences' average media sentiment score of 0.53 beat Aligos Therapeutics' score of 0.46 indicating that Caribou Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aligos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Caribou Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALGS or SPRB?

In the previous week, Aligos Therapeutics and Aligos Therapeutics both had 2 articles in the media. Spruce Biosciences' average media sentiment score of 1.11 beat Aligos Therapeutics' score of 0.46 indicating that Spruce Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aligos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spruce Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor HUMA or ALGS?

In the previous week, Humacyte had 5 more articles in the media than Aligos Therapeutics. MarketBeat recorded 7 mentions for Humacyte and 2 mentions for Aligos Therapeutics. Humacyte's average media sentiment score of 0.59 beat Aligos Therapeutics' score of 0.46 indicating that Humacyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Humacyte 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aligos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Aligos Therapeutics (ALGS) Competitors

$6.84 +0.17 (+2.55%)

As of 02:45 PM Eastern

Compare

ALGS vs. TNYA, CRBU, CNTB, SPRB, and HUMA

Should you buy Aligos Therapeutics stock or one of its competitors? Aligos Therapeutics's main competitors and comparable companies include Tenaya Therapeutics (TNYA), Caribou Biosciences (CRBU), Connect Biopharma (CNTB), Spruce Biosciences (SPRB), and Humacyte (HUMA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aligos Therapeutics compare to Tenaya Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aligos Therapeutics currently has a consensus target price of $38.50, indicating a potential upside of 462.87%. Tenaya Therapeutics has a consensus target price of $4.00, indicating a potential upside of 499.70%. Given Tenaya Therapeutics' higher possible upside, analysts plainly believe Tenaya Therapeutics is more favorable than Aligos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Aligos Therapeutics has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$31.52M	1.36	-$24.19M	-$7.30	N/A
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.53	N/A

Aligos Therapeutics has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.83, suggesting that its share price is 183% more volatile than the broader market.

In the previous week, Tenaya Therapeutics had 4 more articles in the media than Aligos Therapeutics. MarketBeat recorded 6 mentions for Tenaya Therapeutics and 2 mentions for Aligos Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.76 beat Aligos Therapeutics' score of 0.46 indicating that Tenaya Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aligos Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tenaya Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tenaya Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. Tenaya Therapeutics' return on equity of -83.75% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
Tenaya Therapeutics	N/A	-83.75%	-66.53%

Summary

Tenaya Therapeutics beats Aligos Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Aligos Therapeutics compare to Caribou Biosciences?

Aligos Therapeutics (NASDAQ:ALGS) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Aligos Therapeutics has higher revenue and earnings than Caribou Biosciences. Caribou Biosciences is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$31.52M	1.36	-$24.19M	-$7.30	N/A
Caribou Biosciences	$11.16M	15.90	-$148.12M	-$1.08	N/A

Aligos Therapeutics presently has a consensus price target of $38.50, indicating a potential upside of 462.87%. Caribou Biosciences has a consensus price target of $7.75, indicating a potential upside of 368.28%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Caribou Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Caribou Biosciences had 8 more articles in the media than Aligos Therapeutics. MarketBeat recorded 10 mentions for Caribou Biosciences and 2 mentions for Aligos Therapeutics. Caribou Biosciences' average media sentiment score of 0.53 beat Aligos Therapeutics' score of 0.46 indicating that Caribou Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aligos Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Caribou Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aligos Therapeutics has a beta of 2.31, indicating that its share price is 131% more volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.38, indicating that its share price is 138% more volatile than the broader market.

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Caribou Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aligos Therapeutics has a net margin of -241.01% compared to Caribou Biosciences' net margin of -1,030.42%. Caribou Biosciences' return on equity of -89.11% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
Caribou Biosciences	-1,030.42%	-89.11%	-62.47%

Summary

Caribou Biosciences beats Aligos Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Aligos Therapeutics compare to Connect Biopharma?

Aligos Therapeutics (NASDAQ:ALGS) and Connect Biopharma (NASDAQ:CNTB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

Aligos Therapeutics presently has a consensus price target of $38.50, indicating a potential upside of 462.87%. Connect Biopharma has a consensus price target of $7.43, indicating a potential upside of 225.10%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Aligos Therapeutics is more favorable than Connect Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Aligos Therapeutics has a beta of 2.31, indicating that its stock price is 131% more volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.23, indicating that its stock price is 123% less volatile than the broader market.

Connect Biopharma has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. Aligos Therapeutics' return on equity of -160.72% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
Connect Biopharma	N/A	-165.41%	-121.58%

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Aligos Therapeutics had 2 more articles in the media than Connect Biopharma. MarketBeat recorded 2 mentions for Aligos Therapeutics and 0 mentions for Connect Biopharma. Aligos Therapeutics' average media sentiment score of 0.46 beat Connect Biopharma's score of -0.36 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aligos Therapeutics	Neutral
Connect Biopharma	Neutral

Aligos Therapeutics has higher revenue and earnings than Connect Biopharma. Connect Biopharma is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$31.52M	1.36	-$24.19M	-$7.30	N/A
Connect Biopharma	$2.95M	48.73	-$55.48M	-$1.19	N/A

Summary

Aligos Therapeutics beats Connect Biopharma on 12 of the 17 factors compared between the two stocks.

How does Aligos Therapeutics compare to Spruce Biosciences?

Aligos Therapeutics (NASDAQ:ALGS) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 4.3% of Spruce Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Aligos Therapeutics and Aligos Therapeutics both had 2 articles in the media. Spruce Biosciences' average media sentiment score of 1.11 beat Aligos Therapeutics' score of 0.46 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aligos Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spruce Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aligos Therapeutics has higher revenue and earnings than Spruce Biosciences. Spruce Biosciences is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$31.52M	1.36	-$24.19M	-$7.30	N/A
Spruce Biosciences	$4.91M	32.59	-$38.97M	-$39.78	N/A

Aligos Therapeutics currently has a consensus target price of $38.50, indicating a potential upside of 462.87%. Spruce Biosciences has a consensus target price of $159.50, indicating a potential upside of 186.10%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Aligos Therapeutics is more favorable than Spruce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Spruce Biosciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Aligos Therapeutics has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.23, meaning that its share price is 223% more volatile than the broader market.

Spruce Biosciences has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. Spruce Biosciences' return on equity of -123.53% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
Spruce Biosciences	N/A	-123.53%	-90.35%

Summary

Aligos Therapeutics and Spruce Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Aligos Therapeutics compare to Humacyte?

Humacyte (NASDAQ:HUMA) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

Humacyte currently has a consensus target price of $6.11, indicating a potential upside of 822.53%. Aligos Therapeutics has a consensus target price of $38.50, indicating a potential upside of 462.87%. Given Humacyte's higher probable upside, analysts plainly believe Humacyte is more favorable than Aligos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Humacyte has a beta of 2.54, indicating that its share price is 154% more volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.31, indicating that its share price is 131% more volatile than the broader market.

44.7% of Humacyte shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 3.1% of Humacyte shares are held by insiders. Comparatively, 7.8% of Aligos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Humacyte had 5 more articles in the media than Aligos Therapeutics. MarketBeat recorded 7 mentions for Humacyte and 2 mentions for Aligos Therapeutics. Humacyte's average media sentiment score of 0.59 beat Aligos Therapeutics' score of 0.46 indicating that Humacyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Humacyte	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aligos Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aligos Therapeutics has higher revenue and earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	90.15	-$40.83M	-$0.49	N/A
Aligos Therapeutics	$31.52M	1.36	-$24.19M	-$7.30	N/A

Aligos Therapeutics has a net margin of -241.01% compared to Humacyte's net margin of -4,556.29%. Aligos Therapeutics' return on equity of -160.72% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,556.29%	-983.32%	-88.84%
Aligos Therapeutics	-241.01%	-160.72%	-92.30%

Summary

Aligos Therapeutics beats Humacyte on 9 of the 17 factors compared between the two stocks.

Get Aligos Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALGS vs. The Competition

Export

Metric	Aligos Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$42.72M	$3.99B	$7.28B	$12.72B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-0.94	11.76	271.35	24.06
Price / Sales	1.36	1,302.10	605.78	77.99
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	0.79	17.24	11.18	6.39
Net Income	-$24.19M	-$22.72M	$3.46B	$348.39M
7 Day Performance	4.11%	2.86%	1.95%	1.06%
1 Month Performance	67.65%	9.66%	7.28%	5.22%
1 Year Performance	-32.94%	54.43%	24.58%	16.09%

Aligos Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALGS Aligos Therapeutics	2.7941 of 5 stars	$6.84 +2.5%	$38.50 +462.9%	-34.6%	$42.72M	$31.52M	N/A	90
TNYA Tenaya Therapeutics	2.9574 of 5 stars	$0.70 -0.2%	$4.00 +472.7%	-38.3%	$156.63M	N/A	N/A	110
CRBU Caribou Biosciences	2.0772 of 5 stars	$1.56 -0.6%	$7.75 +396.8%	-10.3%	$155.71M	$10.04M	N/A	100
CNTB Connect Biopharma	4.0308 of 5 stars	$2.43 -2.4%	$7.43 +205.7%	+29.0%	$153.00M	$2.95M	N/A	110
SPRB Spruce Biosciences	3.0051 of 5 stars	$52.85 -0.1%	$159.50 +201.8%	+529.0%	$151.68M	$4.91M	N/A	20	News Coverage Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALGS) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aligos Therapeutics (ALGS) Competitors

ALGS vs. TNYA, CRBU, CNTB, SPRB, and HUMA

How does Aligos Therapeutics compare to Tenaya Therapeutics?

Summary

How does Aligos Therapeutics compare to Caribou Biosciences?

Summary

How does Aligos Therapeutics compare to Connect Biopharma?

Summary

How does Aligos Therapeutics compare to Spruce Biosciences?

Summary

How does Aligos Therapeutics compare to Humacyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS vs. The Competition

Aligos Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aligos Therapeutics (ALGS) Competitors

ALGS vs. TNYA, CRBU, CNTB, SPRB, and HUMA

How does Aligos Therapeutics compare to Tenaya Therapeutics?

Do insiders & institutionals believe in ALGS or TNYA?

Do analysts recommend ALGS or TNYA?

Which has better valuation & earnings, ALGS or TNYA?

Which has more risk & volatility, ALGS or TNYA?

Does the media favor ALGS or TNYA?

Is ALGS or TNYA more profitable?

Summary

How does Aligos Therapeutics compare to Caribou Biosciences?

Which has stronger earnings and valuation, ALGS or CRBU?

Do analysts rate ALGS or CRBU?

Does the media favor ALGS or CRBU?

Which has more volatility and risk, ALGS or CRBU?

Do institutionals and insiders have more ownership in ALGS or CRBU?

Is ALGS or CRBU more profitable?

Summary

How does Aligos Therapeutics compare to Connect Biopharma?

Do analysts rate ALGS or CNTB?

Which has more volatility and risk, ALGS or CNTB?

Is ALGS or CNTB more profitable?

Do insiders & institutionals believe in ALGS or CNTB?

Does the media prefer ALGS or CNTB?

Which has higher valuation and earnings, ALGS or CNTB?

Summary

How does Aligos Therapeutics compare to Spruce Biosciences?

Do institutionals & insiders have more ownership in ALGS or SPRB?

Does the media prefer ALGS or SPRB?

Which has preferable earnings & valuation, ALGS or SPRB?

Do analysts recommend ALGS or SPRB?

Which has more risk & volatility, ALGS or SPRB?

Is ALGS or SPRB more profitable?

Summary

How does Aligos Therapeutics compare to Humacyte?

Do analysts recommend HUMA or ALGS?

Which has more risk and volatility, HUMA or ALGS?

Do insiders & institutionals have more ownership in HUMA or ALGS?

Does the media favor HUMA or ALGS?

Which has better valuation & earnings, HUMA or ALGS?

Is HUMA or ALGS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS vs. The Competition

Aligos Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools